Home > Boards > Free Zone > User's Groups > Sector Strategies

>>> Axsome Therapeutics, Inc., a clinical stage biopharmaceutical

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gfp927z Member Profile
 
Followed By 63
Posts 24,147
Boards Moderated 74
Alias Born 03/22/05
160x600 placeholder
Correction to Indianapolis Mass Shooting Article
According to police, the victims include Matthew Alexander, 32 years old; Samaria Blackwell, 19; Amarjeet Johal, 66; Jaswinder Kaur, 64; Jaswinder Singh, 68; Amarjit Sekhon, 48; Karli Smith, 19; and John Weisert, 74. "Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility," at 8:44 p.m. and 9:05 p.m. ET, gave an incorrect spelling for the names of Amarjit Sekhon and Karli Smith.
Roger Stone Is Sued as U.S. Government Alleges Unpaid Taxes -- Update
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 9th Update
Roger Stone Is Sued as U.S. Government Alleges Unpaid Taxes
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 8th Update
Top Company News of the Day
J&J, Morgan Stanley, Coinbase: Stocks That Defined the Week
NASA Picks SpaceX to Build New Lunar Lander -- 2nd Update
Lilly Ends U.S. Use of Single Covid-19 Antibody Drug Alone -- Update
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 7th Update
Stocks End Week With Fresh Records--Update
Top Stories of the Day
NASA Picks SpaceX to Build New Lunar Lander -- Update
FedEx's Limits on Phones in Spotlight After Indianapolis Shooting
When Fed Chief Talks, So Do Listeners -- and They Provide an Earful
Stocks End Week With Fresh Records
Soybeans Rise on Weather Concerns
Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
Indianapolis FedEx Shooting: What We Know So Far -- Update
Boeing 737 MAX Electrical Problem Affects More Locations on Aircraft
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 6th Update
U.S. to Start Consultations With Taiwan Over Currency -- Update
Morgan Stanley Books Archegos Loss, but Profit Hits New High -- 3rd Update
Existing Home Sales Seen Down, New Home Sales Expected to Rise -- Data Week Ahead
No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cases, Company Researchers Say
Indianapolis FedEx Shooting: What We Know So Far
Stocks Look to Extend Winning Streak
gfp927z   Tuesday, 06/04/19 09:50:15 AM
Re: None
Post # of 56 
>>> Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.

<<<





Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences